1-4 of 4
U. Kaiser
Close
Sort by
Journal Articles

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line Treatment of Patients with Indolent and Mantle Cell Lymphomas - First Interim Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).

Mathias J. Rummel, U. von Gruenhagen, N. Niederle, F. Rothmann, H. Ballo, E. Weidmann, M. Welslau, G. Heil, H. Duerk, M. Stauch, C. Losem, A. Matzdorff, C. Balser, K. Schalk, D. Kofahl-Krause, U. Kaiser, W. Knauf, A. Banat, D. Hoelzer, W. Brugger, on behalf of the StiL
Journal: Blood
Blood (2007) 110 (11): 385.
https://doi.org/10.1182/blood.V110.11.385.385
Published: 2007
Journal Articles

A Phase II Trial of Dexamethasone, High-Dose Cytarabine, and Cisplatin (DHAP) in Combination with Rituximab as Salvage Treatment for Patients with Refractory or Relapsed Aggressive Non-Hodgkin’s Lymphoma.

Ulrich J.M. Mey, MD, John W. Strehl, MD, Katjana S. Orlopp, MD, Dimitri Flieger, MD, J. Birkmann, MD, Anthony Ho, MD, U. Kaiser, MD, Andreas Neubauer, MD, Axel G. Glasmacher, MD, Ingo G.H. Schmidt-Wolf, MD
Journal: Blood
Blood (2004) 104 (11): 4618.
https://doi.org/10.1182/blood.V104.11.4618.4618
Published: 2004
Journal Articles

Serum neural cell adhesion molecule differentiates multiple myeloma from paraproteinemias due to other causes

F Ong, U Kaiser, PJ Seelen, J Hermans, PW Wijermans, W de Kieviet, G Jaques, JC Kluin-Nelemans
Journal: Blood
Blood (1996) 87 (2): 712–716.
https://doi.org/10.1182/blood.V87.2.712.bloodjournal872712
Published: 1996
Journal Articles

Serum NCAM: a potential new prognostic marker for multiple myeloma [letter]

U Kaiser, G Jaques, K Havemann, B Auerbach
Journal: Blood
Blood (1994) 83 (3): 871–873.
https://doi.org/10.1182/blood.V83.3.871.871
Published: 1994